NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading STAA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story with a focus on improving financials. The current thesis is stable, as management is working on increasing revenue and achieving profitability.
The market seems to have priced in some expectations of improvement, but the valuation appears stretched compared to peers. There is a low expectations gap, indicating that investors may not be overly optimistic.
Management has demonstrated strong revenue growth and is making progress toward positive net income. However, operating income improvement is mixed, and there is a near-term risk of earnings surprises trending down.
The long-term thesis hinges on continued positive performance from sector bellwethers and management's ability to maintain guidance without cuts. Any negative shifts in the healthcare sector could impact STAA's momentum.
Over the next 1 to 3 years, STAA's trajectory will depend on its ability to sustain growth and navigate sector challenges. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum rose by 44.2 points (from 5.8 to 50.0).
Signal changed from 'mixed' to 'mild_favorable'.
Yes, our read has weakened. The latest earnings beat provided some support, but a sharp drop in the stock price suggests the market may be repricing the reasons to own STAA. This price movement indicates increased pressure on the company's thesis.
as of 2026-07-23
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Growth in China is key for STAAR's overall revenue. A strong performance signals recovery and market share gains.
Confirms:Q2 2026 net sales in China exceed $30 million, indicating strong demand.
Disproves:Q2 2026 net sales in China are under $20 million. This shows ongoing problems.
Why it matters: Better gross margins show STAAR is managing costs well. This means more profit potential.
Confirms:Gross margin exceeds 75% in Q2.
Disproves:Gross margin falls below 70% in Q2.
Why it matters: Strong sales growth would show that STAAR is recovering and gaining market share in China.
Confirms:Q2 net sales growth exceeds 100% year over year compared to Q2 2025.
Disproves:Q2 net sales growth is below 50% year over year.
Why it matters: Improving operating income shows STAAR's cost management is working. This is key for sustainable growth.
Confirms:Operating income in Q2 2026 is positive. This shows good cost control.
Disproves:Operating income in Q2 2026 is still negative. This shows problems with cost management.
Why it matters: A good ERP system can make work easier. It helps the company grow.
Confirms:Management says there were few problems. Teams gave good feedback during the ERP rollout.
Disproves:The ERP rollout has big delays. These issues can hurt operations.
Why it matters: Better operating income shows STAAR is keeping costs low and making money.
Confirms:Operating income will be above breakeven in Q2 2026.
Disproves:Operating income stays negative in Q2 2026. This shows ongoing challenges.
Why it matters: Positive net income shows a big gain in financial performance. This is a good sign.
Confirms:Net income reported as positive for the quarter.
Disproves:Net income remains negative for the quarter.
Why it matters: A drop in revenue growth signals a potential slowdown in the company's momentum. This could affect investor confidence.
Confirms:Q2 revenue growth reported below 10% year over year.
Disproves:Q2 revenue growth remains at or above 10% year over year.
Why it matters: Positive adjusted EBITDA means STAAR is in good financial shape and works well.
Confirms:Adjusted EBITDA for Q2 2026 is over $20 million.
Disproves:Adjusted EBITDA for Q2 2026 falls below $15 million.
Why it matters: A successful launch would indicate strong demand and support margin expansion for STAAR.
Confirms:Sales of EVO+ ICL in China are better than expected in the first six months.
Disproves:Sales of EVO+ ICL in China fail to meet initial expectations.
Why it matters: Better U.S. sales growth would show that EVO ICL is being accepted by surgeons.
Confirms:U.S. net sales growth exceeds 20% year over year in Q2 2026.
Disproves:U.S. net sales growth falls below 10% year over year in Q2 2026.
